Table. 4.

Table. 4.

Colorectal cancer-related disease: characteristics of selected clinical trials included in the review

Reference Type of study Clinical setting/population Sample size Age (year) Daily dose Probiotic species Duration of intervention System Main outcomes
Radvar et al., 2020 (Iran) RCT Rectal cancer 38 Int: 57.58±12.78 Plac: 62.89±13.93 2 times a day 1×108 CFU/g Lactobacillus casei PXN 37, L. rhamnosus PXN 54, Streptococcus thermophilus 81 PXN 66, Bifidobacterium breve PXN 25, L. acidophilus PXN 35, B. longum PXN 30, L. bulgaricus PXN 39, FOS (fructooligosaccharide), magnesium stearate (source: mineral and vegetable), and vegetable capsule (hydroxypropyl methyl cellulose) 6 weeks EORTC QLQ-C30 Positive effect
Golkhalkhali et al., 2018 (Malaysia) RCT Colorectal cancer 140 <18 Two sachets daily 30 billion (CFUs) per sachet Lactobacillus acidophilus BCMCR 12130, L. casei BCMCR 12313, Lactobacillus lactis BCMCR 12451, Bifidobacterium bifidum BCMCR 02290, B. longum BCMCR 02120, and B. infantis BCMCR 02129 8 weeks EORTC QLQ-C30 Positive effect
Lee et al., 2014 (Korea) RCT Colorectal cancer 60 56.18±8.86 Twice a day 2×109 CFU Lacidofil (Lactobacillus rhamnosus R0011 andL. acidophilus R0052) 12 weeks FACT Positive effect
Ohigashi et al., 2011 (Japan) Questionnaire-based study Colorectal cancer 63 63±9 10 mg of Bacillus natto and 30 mg of Lactobacillus acidophilus B. natto and L. acidophilus 3 months SF-36 and EORTC QLQ-C30 Positive effect

RCT, randomized control trial; Int, intervention; Plac, placebo; CFU, colony forming unit; EORTC QLQ-C30, European Organization for Research and Treatment of Cancer’s 30-item QoL questionnaire version 30; FACT, Functional Assessment of Cancer Therapy; SF-36, 36-item short form survey.
Prev Nutr Food Sci 2024;29:237~255 https://doi.org/10.3746/pnf.2024.29.3.237
© Prev. Nutr. Food Sci.
Copyright © 2020 by Preventive Nutrition and Food Science. All right reserved.